Cyprotex (AIM:CRX), the drug discovery technology and information company, will hold its Annual General meeting today. At that meeting, Steve Harris, Chairman, will make the following comments:
"In 2009 we delivered a resilient performance in a difficult market. Revenues hit £5m for the second successive year and we also delivered our second year of profitability. We doubled the number of strategic customers and added 20 new customers in total.
"In the current year, Cyprotex has experienced a strong second quarter and this momentum has continued into July. The Company's revenue and EBITDA performance is in line with market expectations. Furthermore, the Company will open a new laboratory in the coming weeks which will double capacity and allow the launch of our new toxicology offerings."
Cyprotex expects to announce its interim results for the six months to 30 June 2010 on Thursday 12 August 2010.
For further information: Cyprotex PLC Dr Anthony Baxter, Chief Executive Officer John Dootson, Chief Financial Officer Tel: +44 (0) 1625 505 100 email@example.com www.cyprotex.com